PRPF6

PRPF6 provides instructions for a protein called pre-mRNA processing factor 6. This protein is part of the spliceosome, a large cellular machine that trims and joins pieces of genetic messages so they can be read correctly. Specifically, it helps assemble and stabilize a subunit of the spliceosome that is essential for this editing work. Although the protein is needed in cells throughout the body, harmful changes in PRPF6 tend to affect the retina in particular. Research suggests one reason is that PRPF6 also acts at the base of the connecting cilium, a slender structure that photoreceptor (definition: A light-sensing cell in the retina. Rods (used for night and peripheral vision) and cones (used for color and detail) are the two types.) cells rely on to function. For this reason, this form of retinitis pigmentosa has been described as a retinal ciliopathy (definition: A disease caused by a problem with cilia — tiny hair-like structures on cells, including the light-sensing cells in the retina, that the cell needs to work properly.), meaning a disease linked to problems with the cilium.

In the reported cases, PRPF6 changes are linked to retinitis pigmentosa, which typically involves progressive loss of peripheral (side) vision and difficulty seeing in dim light. In one case report, a 34-year-old woman with a PRPF6 variant had signs typical of retinitis pigmentosa, including pale optic discs, narrowed retinal blood vessels, and pigment changes in the retina of both eyes. A separate case report described a variant near the start of the gene that was associated with progressive loss of peripheral vision but maintained good central vision. That observation raised the possibility that different variants within PRPF6 may lead to somewhat different patterns of vision change, though this comes from very few people. Across the wider group of splicing-factor forms of retinitis pigmentosa, researchers have reported early effects in the central retina (macula), thinning of the retinal pigment layer, and pigment deposits in the periphery. Age of onset, severity, and rate of progression can vary from person to person, so a genetic result alone does not predict how any one person's vision will change.

PRPF6 is one of several spliceosome genes that are an established cause of autosomal dominant (definition: An inheritance pattern where a single altered copy of a gene, from just one parent, is enough to cause the condition.) retinitis pigmentosa. Autosomal dominant means a single altered copy of the gene can be enough to cause the condition. The gene was first linked to this disease in 2011, when researchers found a specific change that ran with the disease within a family and disrupted the cell's splicing machinery. Laboratory work has shown that affected cells have PRPF6 protein in the wrong location and retain segments of genetic messages that should have been removed, pointing to faulty splicing as part of the disease process. Further cell studies suggest the trouble may begin with defects in microtubules and the cilium, structures the photoreceptor (definition: A light-sensing cell in the retina. Rods (used for night and peripheral vision) and cones (used for color and detail) are the two types.) depends on to survive.

PRPF6-related retinitis pigmentosa appears to be uncommon among the splicing-factor causes of the disease. In one large study of families with retinitis pigmentosa, disease-causing variants clustered in other splicing-factor genes and none were confirmed in PRPF6. The same study cautioned that certain classes of variant in PRPF6, such as loss-of-function changes, need to be evaluated carefully before being called disease-causing. Some reported PRPF6 changes remain variants of uncertain significance, meaning it is not yet clear whether they cause disease, and the authors called for more study. How the same variant leads to different vision outcomes in different people, and why a protein used throughout the body mainly harms the retina, is still not fully understood.

No therapy aimed specifically at PRPF6 has been approved, and current work is at the laboratory stage. Scientists have created stem cell models from patients with PRPF6 changes, including cell lines carrying specific variants and gene-corrected versions to compare against them. Using retinal pigment epithelium cells grown from a patient, researchers found the cells had abnormal shape, disorganized surface structures, and reduced ability to clear away worn parts of photoreceptors. In cell models, restoring a specific microtubule-modifying enzyme called TTLL3 appeared to rescue cilium number, which the researchers described as a possible future target for treatment. These are early findings in cells, not treatments available to patients, and much more research would be needed before any such approach could be tested in people.

• A cell-based look at the disease mechanism

  Laboratory and cellular research.

  What was found:

  Genes controlling microtubules, the centrosome, and the cilium were most affected, and boosting a tubulin-modifying enzyme rescued cilium number in the mutant cells.

  Why it matters:

  It points to cilium and microtubule defects as an early step and names a possible future therapeutic target.

  Limitation: The rescue results are preliminary and were not tested in people.

• First evidence that PRPF6 causes dominant retinitis pigmentosa

  Human genetic study with supporting cell experiments.

  What was found:

  They identified a missense change that ran with the disease in a family and caused the PRPF6 protein to build up abnormally in the nucleus, along with faulty retention of segments of genetic messages.

  Why it matters:

  This established PRPF6 as a spliceosome gene that can cause dominant retinitis pigmentosa and supported splicing failure as part of the disease mechanism.

  Limitation: The disease-causing change was found in a single family, so it reflects a small number of people.

• How common PRPF6 changes are among splicing-factor RP

  Large observational human cohort with database comparison.

  What was found:

  Confirmed variants clustered in other splicing-factor genes, and none were confirmed in PRPF6; the authors flagged certain PRPF6 variant types as needing further validation.

  Why it matters:

  It shows PRPF6 is a rare cause within this group and highlights the care needed before calling some variants disease-causing.

  Limitation: Findings reflect the populations sampled and may differ elsewhere.

• A newly reported variant with preserved central vision

  Single case report.

  What was found:

  The variant was associated with progressive peripheral vision loss but preserved central sharpness, which the authors suggested may differ from changes at the other end of the gene.

  Why it matters:

  It raises the possibility that where a variant sits in PRPF6 could influence the pattern of vision change.

  Limitation: A single patient cannot establish a general rule, and the observation needs confirmation.

• A case of a variant of uncertain significance

  Single case report.

  What was found:

  Her exam findings were typical of retinitis pigmentosa, and the authors suggested the variant may be associated with the disease while calling for further study.

  Why it matters:

  It illustrates how uncertain variants are handled and why genetic counseling matters when a result is not definitive.

  Limitation: The variant's disease-causing role was not confirmed.

Because PRPF6-related retinitis pigmentosa is usually inherited in an autosomal dominant (definition: An inheritance pattern where a single altered copy of a gene, from just one parent, is enough to cause the condition.) pattern, a parent who carries a disease-causing change has a chance of passing it to each child, and blood relatives may wish to discuss testing with a genetic counselor. Beyond this inheritance point, the general guidance shown on every gene page applies here.

• Does my specific PRPF6 variant have enough evidence to be considered disease-causing, or is it still uncertain?
• Given my exam findings, what pattern of retinitis pigmentosa is most consistent with my results?
• How often should my vision and retina be monitored?
• What does autosomal dominant inheritance mean for my children and other relatives?
• Would testing of family members help clarify whether this variant is causing disease?
• Are there any registered studies for splicing-factor retinitis pigmentosa that might be relevant to discuss?

Confirming a genetic diagnosis with a specialist and a genetic counselor can help put a PRPF6 result in context, especially when a variant is described as uncertain. Regular eye examinations allow a retinal specialist to track how vision is changing over time. To explore research studies, you can use RP Hope's Clinical Trials Finder for personalized screening rather than relying on a gene page to determine eligibility. RP Hope's My RP Pathway offers a guided tour of resources for people at any stage after a diagnosis.